| Title: |
Involvement of the JAK-STAT pathway in the molecular landscape of tyrosine kinase fusion-negative hypereosinophilic syndromes: A nationwide CEREO study |
| Authors: |
Groh, Matthieu; Lefevre, Guillaume; Fenwarth, Laurène; Boudry, Augustin; Fournier, Elise; Marceau-Renaut, Alice; Grardel, Nathalie; Preudhomme, Claude; Duployez, Nicolas; Labro, Mathilde; Wemeau, Mathieu; Daltro de Oliveira, Rafael; Abraham, Julie; Moreau, Stéphane; Barry, Marly; Blanche, Philippe; Bodard, Quentin; Braun, Thorsten; Chebrek, Safia; Decamp, Matthieu; Durel, Cécile-Audrey; Forcade, Edouard; Gerfaud-Valentin, Mathieu; Golfier, Camille; Gourguechon, Clément; Kosmider, Olivier; Martis, Nihal; Melboucy Belkhir, Sarah; Merabet, Fatiha; Rousselot, Philippe; Michon, Adrien; Morice, Cécile; Néel, Antoine; Nicolini, Franck E.; Pascal, Laurent; Pasquier, Florence; Pieragostini, Andrea; Roche-Lestienne, Catherine; Terriou, Louis; Thiebaut-Bertrand, Anne; Viallard, Jean-François; Kahn, Jean-Emmanuel |
| Contributors: |
Service de Génétique CHU Caen; Université de Caen Normandie (UNICAEN); Normandie Université (NU)-Normandie Université (NU)-CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie (CHU Caen Normandie); Normandie Université (NU); Biologie, génétique et thérapies ostéoarticulaires et respiratoires (BIOTARGEN); Normandie Université (NU)-Normandie Université (NU); Infection et inflammation (2I); Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM); M.G.: Consultancy for GlaxoSmithKline and AstraZeneca, speaker forGlaxoSmithKline and Sanofi; M.W.: Consultancy for Novartis; C.M.:Speaker for Abbvie and Lilly; F.E.N.: Consultancy for Sun Pharma Ltd,Novartis, speaker for Incyte Biosciences, board entity for Incyte Biosci-ences, Pfizer, Novartis, BMS-Celgene, research fundings from IncyteBiosciences and Novartis; J.E.K.: consultancy for GlaxoSmithKline andAstraZeneca; G.L.: consultancy for GlaxoSmithKline and AstraZeneca,research fundings from GlaxoSmithKline and AstraZeneca |
| Source: |
ISSN: 0361-8609. |
| Publisher Information: |
CCSD; Wiley |
| Publication Year: |
2024 |
| Collection: |
Université de Versailles Saint-Quentin-en-Yvelines: HAL-UVSQ |
| Subject Terms: |
[SDV]Life Sciences [q-bio] |
| Description: |
International audience ; We investigated using a custom NGS panel of 149 genes the mutational landscape of 64 consecutive adult patients with tyrosine kinase fusion-negative hypereosinophilia (HE)/hypereosinophilic syndrome (HES) harboring features suggestive of myeloid neoplasm. At least one mutation was reported in 50/64 (78%) patients (compared to 8/44 (18%) patients with idiopathic HE/HES/HEUS used as controls; p |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1002/ajh.27306 |
| Availability: |
https://hal.science/hal-04608501; https://doi.org/10.1002/ajh.27306 |
| Accession Number: |
edsbas.D0C60E05 |
| Database: |
BASE |